Table 5.
Specifications of thromboembolic events
| IBD (n = 618) | Controls* (n = 618) | Rheumatoid arthritis (n = 243) | Coeliac disease (n = 207) | |
| Patients with TE (n) | 38† | 10† | 5 | 2 |
| One TE | 30 | 9 | 5 | 2 |
| Two TE | 7 | – | – | – |
| Three TE | 1 | 1 | – | – |
| Total number of TEs | 47 | 12 | 5 | 2 |
| Age at first TE (median (range)) | 47 (18–84) | 35 (22–69) | 56 (33–64) | 34 and 53 |
| Site of TE (n) | ||||
| Deep vein | 23 | 6 | 5 | 2 |
| PE | 14 | 6 | – | – |
| Subclavian vein | 4 | – | – | – |
| Arm vein | 3 | – | – | – |
| Other‡ | 3 | – | – | – |
| Clinical risk factors (n) | ||||
| Flight§ | 3 | 1 | 1 | – |
| Postoperative | 5 | 1 | 1 | – |
| Injury | 2 | 1 | – | 1 |
| Pregnancy | – | 2 | 1 | – |
| OC | 5 | 2 | 1 | – |
| CVC | 5 | – | – | – |
| IBD specific factors (n) | ||||
| Clinical activity | 18 | |||
| Fistula | 5 | |||
| Abscess | 1 | |||
| Stenosis | 9 | |||
| IBD specific therapy (n) | ||||
| 5-ASA | 17 | |||
| Steroids | 13 | |||
| AZA | 5 | |||
*Control group matched to the IBD group by age (±3 years) and sex.
†χ2 test, p<0.001; OR = 3.6 (95% CI 1.7–7.8) adjusted for the risk factors operation, injuries, oral contraceptive use, pregnancy, BMI, and smoking in the logistic regression model.
‡Cavernous sinus thrombosis, mesenteric vein thrombosis, or superior caval vein thrombosis.
§Travelling by plane, bus or car, ⩾4 hours.
IBD, inflammatory bowel disease; TE, thromboembolism; PE, pulmonary embolism; OC, oral contraceptive use or hormone substitution; CVC, central venous catheter; 5-ASA, 5-aminosalicylic acid; AZA, azathioprine.